P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring systemPepijn W. A. Thomas, Frank Hoentjen, Robert West et al.|Journal of Crohn s and Colitis|2020Cited by 3
P626 Higher discontinuation rates of anti-TNF therapy in elderly IBD patients compared with a younger age group: results from a prospective registryLisa Smits, Frank Hoentjen, Robert West et al.|Journal of Crohn s and Colitis|2019Cited by 1
DOP51 De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalationPepijn W. A. Thomas, Frank Hoentjen, Lisa Smits et al.|Journal of Crohn s and Colitis|2021Cited by 0
P269 Real-world impact of biological therapies on work impairment and quality of life in Inflammatory Bowel Disease patientsPepijn W. A. Thomas, Frank Hoentjen, M. Russel et al.|Journal of Crohn s and Colitis|2021Cited by 0
P374 Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s diseaseEdo Savelkoul, Frank Hoentjen, M. Maas et al.|Journal of Crohn s and Colitis|2021Cited by 0